Yang Hannah, Elsayed Yosra, Zablocki Victoria, Bailey Beth
Central Michigan University College of Medicine, Mount Pleasant, MI, USA.
Matern Child Health J. 2025 May;29(5):599-603. doi: 10.1007/s10995-025-04091-w. Epub 2025 Apr 26.
The aim of this pilot study was to examine, using observational data, birth outcomes following the use of antiviral therapy in pregnancy.
This retrospective chart review study involved patients diagnosed with COVID-19 who received care at a single university-affiliated obstetrics practice grouped as having received, or not received, Ritonavir-Boosted Nirmatrelvir (NMV-r). Participant background information and birth outcomes were extracted and analyzed.
Of 141 patients, nine were prescribed and took a course of NMV-r. Infants born to patients who were pregnantand took NMV-r had significantly shorter hospital stays (average of 2.5 days less) compared to infants born to patients who did not take NMV-r. In addition, there were multiple non-significant but clinically meaningful group differences: more than 10% of those who did not take NMV-r delivered preterm, while all those who took NMV-r delivered after 37 weeks, and infants born to those who did not take NMV-r were three times more likely to be admitted to the NICU compared to infants born to those who took a course of NMV-r.
Patients who are pregnant andtake NMV-r as treatment for COVID-19 appear to have better birth outcomes than those who do not, with no identified adverse effects in this small convenience sample. Based on this pilot study, NMV-r may improve clinical outcomes for obstetrics patients who contract COVID-19 during pregnancy.
本初步研究的目的是利用观察数据，研究孕期使用抗病毒治疗后的分娩结局。
这项回顾性病历审查研究涉及在一家大学附属产科诊所接受治疗的确诊为COVID-19的患者，这些患者被分为接受或未接受利托那韦增强型奈玛特韦（NMV-r）治疗。提取并分析了参与者的背景信息和分娩结局。
在141名患者中，有9名患者被开具并服用了一个疗程的NMV-r。与未服用NMV-r的患者所生婴儿相比，怀孕并服用NMV-r的患者所生婴儿的住院时间明显更短（平均少2.5天）。此外，还存在多个无统计学意义但具有临床意义的组间差异：未服用NMV-r的患者中有超过10%早产，而所有服用NMV-r的患者均在37周后分娩，未服用NMV-r的患者所生婴儿进入新生儿重症监护病房（NICU）的可能性是服用一个疗程NMV-r的患者所生婴儿的三倍。
怀孕并将NMV-r作为COVID-19治疗药物的患者似乎比分娩结局更优，在这个小样本便利抽样中未发现不良反应。基于这项初步研究，NMV-r可能改善孕期感染COVID-19的产科患者的临床结局。
